medigraphic.com

2015, Number 1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2015; 16 (1)

Importance of the interpretation of the total cholesterol and triglyceride content for the diagnosis of dyslipidemias

Morejón RO,Triana MME

Language: Spanish
References: 16
Page:
PDF size: 261.51 Kb.


ABSTRACT

Objective: to describe the importance of right interpretation of the total cholesterol and triglyceride content for the diagnosis of the dyslipidemias.
Methods: evaluation of 2 159 results of study of lipid analyses made at the laboratory of biochemistry of the Institute of Angiology and Vascular Surgery from January 2008 to January 2009. The experts' recommendations and diagnosticians' references were used to decide whether the results were positive or not.
Results: it was found that the cholesterol indexes were positive in 32 % of the analyses according to the recommendations and in 9.96 % according to the references. Similarly, triglycerides indexes were positive in 43.14 % and 38.96 %, respectively. These findings indicated that applying the criteria of the diagnosticians' references, hypercholesterolemia or hypertriglyceridemia was not duly diagnosed in 68.88 % and 9.68 of analyses, respectively. According to the experts' recommendations, the order of frequency of dyslipidemias was hypertriglyceridaemia (42.42 %), hypercholesterolemia (30.33 %) and combined hyperlipidemia (27.25 %). Considering the severity of the two first, it was observed that hypercholesterolemia was mild (59.89 %), moderate (31.59 %) and severe (8.52 %) whereas hypertriglyceridemia was moderate (51.67 %) and severe (48.33 %).
Conclusions: the correct interpretation of results of the lipid study is highly significant and represents a social contribution to diagnosis of dyslipidemia.


REFERENCES

  1. Cohen S, Oates JA, Spilker B, Zegerc SL. Establishing the research infrastructure to develop and classify clinical biomarkers. In: Dowing GJ, editor. Biomarkers and surrogate endpoint: Clinical research and applications. New York: Elsevier; 2000. p. 307-14.

  2. World Health Organization. Biomarkers in risk assessment: validity and validation. Geneva: WHO; 2001 [cited 2013 Nov 30]. Available from: http://www.inchem.org/documents/ehc/ehc/ehc222.htm

  3. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic. Events. Circulation. 2004;109 (suppl IV):6-19.

  4. Meigs JM, Hu FB, Rifai N, Manson JAE. Biomarkers of endothelial dysfunction and risk of type 2 Diabetes Mellitus. JAMA. 2004;291:1978-86.

  5. Rubens HB. Triglycerides and coronary herat disease: implications of recent clinical trials [review]. J Cardiovasc Risk. 2000;7:339-45.

  6. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with Simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363 (9411):757-67.

  7. MAC/BHF Heart protection study of cholesterol lowering with Simvastatin in 5963 persons with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005- 16.

  8. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811-22.

  9. Organización Mundial de la salud. Las enfermedades no transmisibles, un problema de salud de primer orden para el siglo xxi. Estadísticas Sanitarias Mundiales. ginebra: OMS; 2012 [citado 30 Nov 2013]:1-178. Disponible en: http://www.who.int/healthinfo/ES_WHS2012_Full.pdf

  10. Ministerio de Salud Pública. Anuario estadístico de Cuba 2012. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2012 [citado 30 Nov 2013]. Disponible en:http://www.files.sld.cu/dne/files/2013/04/anuario_2012.pdf

  11. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation. 2002;106:3143-421.

  12. Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J Lipid Res. 2013;54(11):2946-9.

  13. LU H, Daugherty A. Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol. 2011;22:322-3.

  14. Vergeer M, Holleboom AG, Kastelein JJP, Kuivenhoven JA.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res. 2010 [cited 2013 Nov 8];51:2058-73. Available from:http://www.jlr.org/content/51/8/2058.full.pdf

  15. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, de Backer G, Graham I, et al. Atherosclerosis. 2011 [cited 2013 Nov 30];217(Suppl 1):S1-44. Available from:http://www.sciencedirect.com/science/article/pii/S0021915011004898 doi: 10.1016/j.atherosclerosis.2011.06.012

  16. Bronas UG, Salisbury D. Clinical strategies for managing dyslipidemias. Am J Lifestyle Med. 2013 [cited 2014 Jan 5];20(10):1-16. Available from:http://ajl.sagepub.com/content/early/2013/10/20/1559827613507534.full.pdf+h tmldoi:10.177/1559827613507534




2020     |     www.medigraphic.com